Predicting individual survival after gastric cancer resection: Validation of a U.S.-derived nomogram at a single high-volume center in Europe

Annals of Surgery

Volumn 243, Issue 1, 2006, Pages 74-81

  Novotny, Alexander R ^a   Schuhmacher, Christoph ^a   Busch, Raymonde ^a   Kattan, Michael W ^b   Brennan, Murray F ^b   Siewert, Jörg Rüdiger ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CALIBRATION; CANCER CENTER; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EUROPE; FEMALE; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PRIORITY JOURNAL; STOMACH CANCER; UNITED STATES; VALIDATION PROCESS;

ADENOCARCINOMA; FEMALE; GASTRECTOMY; GERMANY; HUMANS; MALE; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 30144444773     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000194088.81126.85     Document Type: Article

References (49)

1. Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for disease-specific survival after an RO resection for gastric carcinoma. J Clin Oncol. 2003;21:3647-3650.
2. Kajitani T. Japanese Research Society for the Study of Gastric Cancer: the general rules for gastric cancer study in Surgery and Pathology. Jpn J Surg. 1981;11:127-145.
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Pathol Microbiol Scand. 1965;64:31.
4. Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449-461.
5. Harrison LE, Karpeh MS, Brennan MF. Proximal gastric cancers resected via a transabdominal-only approach: results and comparisons to distal adenocarcinoma of the stomach. Ann Surg. 1997;225:678-683.
6. Harrell FE Jr, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA. 1982;247:2543-2546.
7. Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg. 1997;84:1651-1664.
8. Bottcher K, Becker K, Busch R, et al. Prognostic factors in stomach cancer: results of a uni- and multivariate analysis. Chirurg. 1992;63: 656-661.
9. Baba H, Korenaga D, Okamura T, et al. Prognostic factors in gastric cancer with serosal invasion: univariate and multivariate analyses. Arch Surg. 1989;124:1061-1064.
10. Bozzetti F, Bonfanti G, Morabito A, et al. A multifactorial approach for the prognosis of patients with carcinoma of the stomach after curative resection. Surg Gynecol Obstet. 1986;162:229-234.
11. Korenaga D, Haraguchi M, Okamura T, et al. DNA ploidy and tumor invasion in human gastric cancer: histopathologic differentiation. Arch Surg. 1989;124:314-318.
12. Maruyama K. The most important prognostic factors for gastric cancer patients: a study using univariate and multivariate analyses. Scand J Gastroenterol 1987;22(suppl 133):63.
13. Shiu MH, Perrotti M, Brennan MF. Adenocarcinoma of the stomach: a multivariate analysis of clinical, pathologic and treatment factors. Hepatogastroenterology. 1989;36:7-12.
14. Msika S, Chastang C, Houry S, et al. Lymph node involvement as the only prognostic factor in curative resected gastric carcinoma: a multivariate analysis. World J Surg. 1989;13:118-123.
15. Siewert JR, Stein HJ, Bottcher K. Lymphadenectomy in tumors of the upper gastrointestinal tract. Chirurg. 1996;67:877-888.
16. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994;54:2900-2907.
17. Keller G, Rotter M, Vogelsang H, et al. Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract: relation to clinicopathological data and family history. Am J Pathol. 1995;147:593-600.
18. Nakashima H, Inoue H, Mori M, et al. Microsatellite instability in Japanese gastric cancer. Cancer. 1995;75:1503-1507.
19. Seruca R, Santos NR, David L, et al. Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. Int J Cancer 1995;64:32-36.
20. Lee HS, Lee HK, Kim HS, et al. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003;200:39-46.
21. Akama Y, Yasui W, Yokozaki H, et al. Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn J Cancer Res. 1995; 86:617-621.
22. Okusa Y, Ichikura T, Mochizuki H. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma. Cancer. 1999;85:1033-1038.
23. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer: its correlation with long-term survival of patients. Cancer. 1993;72:3179-3184.
24. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51:1034-1038.
25. El Rifai W, Frierson HF Jr, Harper JC, et al. Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer. 2001;92:832-838.
26. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
27. Lee HS, Lee HK, Kim HS, et al. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001;92:1427-1434.
28. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
29. Villacampa MM, del Carmen Galan M, Medina MM, et al. Adjuvant chemotherapy for poor prognosis gastric cancer: our experience. Ann Oncol. 2000;11(suppl 4):71.
30. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. New York: John Wiley & Sons, 2002.
31. Cirera L, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol. 1999;17:3810-3815.
32. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35:1059-1064.
33. Neri B, Cini G, Andreoli F, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer. 2001;84:878-880.
34. Kath R, Fiehler J, Schneider CP, et al. Gastric cancer in very young adults: apropos four patients and a review of the literature. J Cancer Res Clin Oncol. 2000;126:233-237.
35. Kim DY, Ryu SY, Kim YJ, et al. Clinicopathological characteristics of gastric carcinoma in young patients. Langenbecks Arch Surg. 2003;388: 245-249.
36. Lai IR, Lee WJ, Chen CN, et al. Gastric cancer in the young. Hepatogastroenterology. 1997;44:1641-1645.
37. Koea JB, Karpeh MS, Brennan MF. Gastric cancer in young patients: demographic, clinicopathological, and prognostic factors in 92 patients. Ann Surg Oncol. 2000;7:346-351.
38. Medina-Franco H, Heslin MJ, Cortes-Gonzalez R. Clinicopathological characteristics of gastric carcinoma in young and elderly patients: a comparative study. Ann Surg Oncol. 2000;7:515-519.
39. Kokkola A, Sipponen P. Gastric carcinoma in young adults. Hepatogastroenterology. 2001;48:1552-1555.
40. Nakamura T, Yao T, Niho Y, et al. A clinicopathological study in young patients with gastric carcinoma. J Surg Oncol. 1999;71:214-219.
41. Ramos-De la Medina A, Salgado-Nesme N, Torres-Villalobos G, et al. Clinicopathologic characteristics of gastric cancer in a young patient population. J Gastrointest Surg. 2004;8:240-244.
42. Siewert JR, Holscher AH, Becker K, et al. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58:25-32.
43. Wagner PK, Ramaswamy A, Ruschoff J, et al. Lymph node counts in the upper abdomen: anatomical basis for lymphadenectomy in gastric cancer. Br J Surg. 1991;78:825-827.
44. Yasuda K, Adachi Y, Shiraishi N, et al. Prognostic effect of lymph node micrometastasis in patients with histologically node-negative gastric cancer. Ann Surg Oncol. 2002;9:771-774.
45. Siewert JR, Kestlmeier R, Busch R, et al. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg. 1996;83:1144-1147.
46. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
47. Nekarda H, Gess C, Stark M, et al. Immunocytochemically detected free peritoneal tumour cells (FPTC) are a strong prognostic factor in gastric carcinoma. Br J Cancer. 1999;79:611-619.
48. Talamonti MS, Kim SP, Yao KA, et al. Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery. 2003;134:720-727.
49. Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol. 2003;22:249.